Document Detail


Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?
MedLine Citation:
PMID:  10213344     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the preceding sections we have described the potential for using cell cycle regulatory molecules as targets for drug development within the cardiovascular system. Opportunities for affecting the expression and activities of selected cell cycle regulatory molecules exist in interventional cardiological procedures such as PTCA to limit specifically the intimal hyperplasia of vascular smooth muscle cells that occurs following angioplasty. In addition, the potential for targeting the cardiac myocyte cell cycle to re-initiate cell division in a controlled manner would provide a suitable approach for repairing damaged areas of myocardial tissue following an infarct. Although this approach has not been demonstrated to date in vivo, data from transgenic mouse models and in vitro studies have implicated the cell cycle as a suitable target for manipulation. The next few years will enable the feasibility of this approach to be demonstrated.
Authors:
J M Li; G Brooks
Related Documents :
15365764 - Hym1p affects cell cycle progression in saccharomyces cerevisiae.
12464634 - Cell identity and sexual development in cryptococcus neoformans are controlled by the m...
10644764 - Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates r...
19201464 - Cyclic adp-ribose links metabolism to multiple fission in the dinoflagellate crypthecod...
21115894 - Effect of hyperbaric oxygen on the anticancer effect of artemisinin on molt-4 human leu...
20118274 - Tricarboxylic acid cycle activity regulates tomato root growth via effects on secondary...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  European heart journal     Volume:  20     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1999 Mar 
Date Detail:
Created Date:  1999-06-08     Completed Date:  1999-06-08     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  406-20     Citation Subset:  IM    
Affiliation:
Cardiovascular Cellular and Molecular Biology, Cardiovascular Research, The Rayne Institute, St. Thomas' Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiovascular Diseases / drug therapy,  metabolism
Cardiovascular System / drug effects,  metabolism*
Cell Cycle / drug effects,  physiology
Cyclin-Dependent Kinases / antagonists & inhibitors,  genetics,  metabolism*
Cyclins / genetics,  metabolism*
Endothelium, Vascular / cytology,  drug effects,  metabolism
Humans
Mice
Muscle, Smooth, Vascular / cytology,  drug effects,  metabolism
Myocardium / cytology,  metabolism
Oligodeoxyribonucleotides, Antisense / pharmacology*
RNA, Messenger / biosynthesis
Grant Support
ID/Acronym/Agency:
//Wellcome Trust
Chemical
Reg. No./Substance:
0/Cyclins; 0/Oligodeoxyribonucleotides, Antisense; 0/RNA, Messenger; EC 2.7.11.22/Cyclin-Dependent Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  L4-5 disk lesion resulting in back pain with bowel, bladder and sexual dysfunction without parapares...
Next Document:  Incidence and aetiology of heart failure; a population-based study.